186 related articles for article (PubMed ID: 26844569)
1. The Link Between CD6 and Autoimmunity: Genetic and Cellular Associations.
Kofler DM; Farkas A; von Bergwelt-Baildon M; Hafler DA
Curr Drug Targets; 2016; 17(6):651-65. PubMed ID: 26844569
[TBL] [Abstract][Full Text] [Related]
2. Fine mapping and functional analysis of the multiple sclerosis risk gene CD6.
Swaminathan B; Cuapio A; Alloza I; Matesanz F; Alcina A; García-Barcina M; Fedetz M; Fernández O; Lucas M; Orpez T; Pinto-Medel MJ; Otaegui D; Olascoaga J; Urcelay E; Ortiz MA; Arroyo R; Oksenberg JR; Antigüedad A; Tolosa E; Vandenbroeck K
PLoS One; 2013; 8(4):e62376. PubMed ID: 23638056
[TBL] [Abstract][Full Text] [Related]
3. The CD6 multiple sclerosis susceptibility allele is associated with alterations in CD4+ T cell proliferation.
Kofler DM; Severson CA; Mousissian N; De Jager PL; Hafler DA
J Immunol; 2011 Sep; 187(6):3286-91. PubMed ID: 21849685
[TBL] [Abstract][Full Text] [Related]
4. ALCAM and CD6--multiple sclerosis risk factors.
Wagner M; Bilinska M; Pokryszko-Dragan A; Sobczynski M; Cyrul M; Kusnierczyk P; Jasek M
J Neuroimmunol; 2014 Nov; 276(1-2):98-103. PubMed ID: 25216742
[TBL] [Abstract][Full Text] [Related]
5. Critical Role of CD6highCD4+ T Cells in Driving Th1/Th17 Cell Immune Responses and Mucosal Inflammation in IBD.
Ma C; Wu W; Lin R; Ge Y; Zhang C; Sun S; Cong Y; Li X; Liu Z
J Crohns Colitis; 2019 Mar; 13(4):510-524. PubMed ID: 30395204
[TBL] [Abstract][Full Text] [Related]
6. CD318 is a ligand for CD6.
Enyindah-Asonye G; Li Y; Ruth JH; Spassov DS; Hebron KE; Zijlstra A; Moasser MM; Wang B; Singer NG; Cui H; Ohara RA; Rasmussen SM; Fox DA; Lin F
Proc Natl Acad Sci U S A; 2017 Aug; 114(33):E6912-E6921. PubMed ID: 28760953
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab.
Hernández P; Moreno E; Aira LE; Rodríguez PC
Curr Drug Targets; 2016; 17(6):666-77. PubMed ID: 26844560
[TBL] [Abstract][Full Text] [Related]
8. Associations of CD6, TNFRSF1A and IRF8 polymorphisms with risk of inflammatory demyelinating diseases.
Park TJ; Kim HJ; Kim JH; Bae JS; Cheong HS; Park BL; Shin HD
Neuropathol Appl Neurobiol; 2013 Aug; 39(5):519-30. PubMed ID: 22994200
[TBL] [Abstract][Full Text] [Related]
9. Expression and characterization of a novel CD6 ligand in cells derived from joint and epithelial tissues.
Saifullah MK; Fox DA; Sarkar S; Abidi SM; Endres J; Piktel J; Haqqi TM; Singer NG
J Immunol; 2004 Nov; 173(10):6125-33. PubMed ID: 15528349
[TBL] [Abstract][Full Text] [Related]
10. T cell activation regulates CD6 alternative splicing by transcription dynamics and SRSF1.
da Glória VG; Martins de Araújo M; Mafalda Santos A; Leal R; de Almeida SF; Carmo AM; Moreira A
J Immunol; 2014 Jul; 193(1):391-9. PubMed ID: 24890719
[TBL] [Abstract][Full Text] [Related]
11. The genetic association of variants in CD6, TNFRSF1A and IRF8 to multiple sclerosis: a multicenter case-control study.
International Multiple Sclerosis Genetics Consortium
PLoS One; 2011 Apr; 6(4):e18813. PubMed ID: 21552549
[TBL] [Abstract][Full Text] [Related]
12. Validation of the CD6 and TNFRSF1A loci as risk factors for multiple sclerosis in Spain.
Swaminathan B; Matesanz F; Cavanillas ML; Alloza I; Otaegui D; Olascoaga J; Cénit MC; de las Heras V; Barcina MG; Arroyo R; Alcina A; Fernandez O; Antigüedad A; Urcelay E; Vandenbroeck K
J Neuroimmunol; 2010 Jun; 223(1-2):100-3. PubMed ID: 20430450
[TBL] [Abstract][Full Text] [Related]
13. Modulation of CD4 T cell function via CD6-targeting.
Freitas RF; Basto A; Almeida SCP; Santos RF; Gonçalves CM; Corria-Osorio J; Carvalho T; Carmo AM; Oliveira VG; Leon K; Graca L
EBioMedicine; 2019 Sep; 47():427-435. PubMed ID: 31481324
[TBL] [Abstract][Full Text] [Related]
14. Tuning T Cell Activation: The Function of CD6 At the Immunological Synapse and in T Cell Responses.
Santos RF; Oliveira L; Carmo AM
Curr Drug Targets; 2016; 17(6):630-9. PubMed ID: 26028048
[TBL] [Abstract][Full Text] [Related]
15. Structures of CD6 and Its Ligand CD166 Give Insight into Their Interaction.
Chappell PE; Garner LI; Yan J; Metcalfe C; Hatherley D; Johnson S; Robinson CV; Lea SM; Brown MH
Structure; 2015 Aug; 23(8):1426-1436. PubMed ID: 26146185
[TBL] [Abstract][Full Text] [Related]
16. Involvement of CD166 in the activation of human gamma delta T cells by tumor cells sensitized with nonpeptide antigens.
Kato Y; Tanaka Y; Hayashi M; Okawa K; Minato N
J Immunol; 2006 Jul; 177(2):877-84. PubMed ID: 16818742
[TBL] [Abstract][Full Text] [Related]
17. CD6 as a potential target for treating multiple sclerosis.
Li Y; Singer NG; Whitbred J; Bowen MA; Fox DA; Lin F
Proc Natl Acad Sci U S A; 2017 Mar; 114(10):2687-2692. PubMed ID: 28209777
[TBL] [Abstract][Full Text] [Related]
18. High CD6 and low chemokine receptor expression on peripheral blood lymphocytes correlates with MRI gadolinium enhancement in MS.
Jurewicz A; Zaleski K; Domowicz M; Selmaj K
J Neuroimmunol; 2014 Nov; 276(1-2):187-94. PubMed ID: 25242631
[TBL] [Abstract][Full Text] [Related]
19. CD6 as a therapeutic target in autoimmune diseases: successes and challenges.
Pinto M; Carmo AM
BioDrugs; 2013 Jun; 27(3):191-202. PubMed ID: 23568178
[TBL] [Abstract][Full Text] [Related]
20. Dynamic coupling of ALCAM to the actin cortex strengthens cell adhesion to CD6.
Te Riet J; Helenius J; Strohmeyer N; Cambi A; Figdor CG; Müller DJ
J Cell Sci; 2014 Apr; 127(Pt 7):1595-606. PubMed ID: 24496453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
